STOCK TITAN

4.5M Palisade Bio (PALI) shares reported by Squadron and partners

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Squadron Master Fund LP and related parties report beneficial ownership of 4,500,000 shares of Palisade Bio, Inc. common stock, representing 3.0% of the class. The stake is reported on a Schedule 13G/A as of an event date of 12/31/2025.

The ownership percentage is based on 149,003,210 shares of common stock outstanding as of November 5, 2025, as stated in Palisade Bio’s Form 10-Q filed November 10, 2025. Squadron Capital Management, LLC, as investment adviser to private funds including Squadron Master Fund LP, may be deemed a beneficial owner, and partners Matthew Sesterhenn and William Blank may also be deemed beneficial owners.

All report 0 shares with sole voting or dispositive power and 4,500,000 shares with shared voting and dispositive power. They certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Palisade Bio.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Squadron Master Fund LP
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:02/17/2026
Squadron Capital Management LLC
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner
Date:02/17/2026
Matthew Sesterhenn
Signature:/s/ Matthew Sesterhenn
Name/Title:Matthew Sesterhenn
Date:02/17/2026
William Blank
Signature:/s/ William Blank
Name/Title:William Blank
Date:02/17/2026

FAQ

What stake in Palisade Bio (PALI) does Squadron Master Fund report?

Squadron Master Fund LP reports beneficial ownership of 4,500,000 shares of Palisade Bio common stock. This represents 3.0% of the outstanding common shares, based on 149,003,210 shares outstanding as of November 5, 2025, per the company’s Form 10-Q.

Which entities and individuals are reporting ownership in Palisade Bio (PALI)?

The reporting persons are Squadron Master Fund LP, Squadron Capital Management, LLC, and individuals Matthew Sesterhenn and William Blank. Each reports beneficial ownership of 4,500,000 shares, corresponding to 3.0% of Palisade Bio’s common stock.

How is the 3.0% Palisade Bio (PALI) ownership percentage calculated?

The 3.0% ownership is calculated using 149,003,210 shares of Palisade Bio common stock outstanding. That share count comes from the issuer’s Form 10-Q, which states this number as outstanding as of November 5, 2025, filed with the SEC on November 10, 2025.

Do Squadron and its principals have sole or shared voting power over Palisade Bio (PALI) shares?

Each reporting person discloses 0 shares with sole voting or dispositive power and 4,500,000 shares with shared voting and dispositive power. This means decisions over those shares are made jointly rather than individually by any single reporting person.

Is Squadron Capital Management, LLC a beneficial owner of Palisade Bio (PALI) shares?

Squadron Capital Management, LLC, an investment adviser to private funds including Squadron Master Fund LP, may be deemed a beneficial owner of the funds’ Palisade Bio shares. The filing notes that Squadron and the individual partners expressly disclaim beneficial ownership under Rule 13d-4.

What is the purpose of Squadron’s Palisade Bio (PALI) share holdings according to the filing?

The reporting persons certify the Palisade Bio securities were acquired and are held in the ordinary course of business. They state the shares were not acquired to change or influence control of the issuer, except for activities solely tied to nominations under Rule 14a-11.

What type of SEC filing did Squadron use to report its Palisade Bio (PALI) position?

The position is disclosed on an amended Schedule 13G/A. This form is used to report beneficial ownership of more than a certain threshold when the holder qualifies for a passive or similar reporting status, as opposed to a control-oriented Schedule 13D filing.
Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

PALI Latest News

PALI Latest SEC Filings

PALI Stock Data

258.12M
6.13M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CARLSBAD